1. Home
  2. Directory
  3. California
  4. San Francisco
  5. Internal Medicine
  6. NPI Profile
  7. Prescriptions 1144647421

DR. ANA ISABEL VELAZQUEZ MD MSC
Prescription History 1144647421
Internal Medicine - Medical Oncology in San Francisco, CA


Quality Rating: 91.85 out of 100 score

NPI Status: Active since March 25, 2014

Contact Information

1001 POTRERO AVE
BUILDING 5, SUITE 4C
SAN FRANCISCO, CA
ZIP 94110
Phone: (628) 206-2406

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. ANA ISABEL VELAZQUEZ MD MSC, an active Medical Oncology specialist practicing in San Francisco, CA. Our medical registry currently tracks 3 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 83 documented patient claims. Among these therapy options, the most frequently utilized medication is Tagrisso, which accounts for 55 claims alone.

Medication Index

E
O
T
No matching medications currently found on file.

Erlotinib Hcl

Generic Formulation: Erlotinib HclSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
CA State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills17.6
Peer Average Days Supply519
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,026.41 across this reporting matrix range.

Provider Avg Cost Per Claim

$463.57

State Avg Cost Per Claim

$1,385.81

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinazoline derivative and ANTINEOPLASTIC AGENT that functions as a PROTEIN KINASE INHIBITOR for EGFR associated tyrosine kinase. It is used in the treatment of NON-SMALL CELL LUNG CANCER.

Therapeutic Applications

Erlotinib is used to treat lung and pancreatic cancer. It works by slowing or stopping the growth of cancer cells.

Ondansetron Hcl

Generic Formulation: Ondansetron HclSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 237
CA State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills30.5
Peer Average Days Supply570
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $254.93 across this reporting matrix range.

Provider Avg Cost Per Claim

$17.00

State Avg Cost Per Claim

$8.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. It works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Tagrisso

Generic Formulation: Osimertinib MesylateSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 55
30-Day Fills 55.0
Days Supply 1,650
CA State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills32.4
Peer Average Days Supply969
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 71.9% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $924,532.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$16,809.67

State Avg Cost Per Claim

$16,956.40

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat lung cancer. Osimertinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. It binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. ANA ISABEL VELAZQUEZ MD MSC provides transparency into local medical care patterns within San Francisco, CA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Medical Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.